Is the FDA Too Tough on Medical Device Makers?

Knowledge at Wharton

Ask about Knowledge at Wharton

Episode Description

Are the FDA's medical device regulations too hard, too soft, or just right? Wharton research indicates that the agency is on the right track. More: http://knlg.net/1Cb8KUR 📂 Health Care Management;Public Policy 🏷️ Research

Read the full transcriptHide the full transcript
  1. what we're doing in this paper is examining the approach that the FDA takes to medical device regulation and
  2. asking the question is it optimal or how close to optimal is it there's a raging
  3. debate about whether the FDA is too difficult on medical device regulation whether it's too hard for device
  4. manufacturers to get their device through the regulatory process or whether they're two lakhs and let too
  5. many potentially harmful devices through the process and so our research asked the question how much information does
  6. the FDA regulatory process generate for the market to use in deciding what to device to use in a given patient and
  7. should they require more information or less information and that's what our paper seeks to address
  8. what we did is we compared the behavior of devices in the US which has a much more difficult and rigorous regulatory
  9. standard to the European Union which has a much less informational requirements to get their devices through the
  10. approval process so we compared how the devices that were common in both markets
  11. how their market share evolved over time and we compare that to devices that were
  12. only offered in the EU which is what typically happens since the you market is much easier to answer there's many
  13. more devices and we examined how those market shares evolved over time and use that information to make inferences
  14. about the information that was being generated by the regulatory process and and then translate that into real
  15. consumer welfare measures what we found is that the US FDA regulatory process for the devices we
  16. looked at which were second generation stents cardiac stents was pretty close to optimal and while the EU which has
  17. very lacks regulatory standards was 22 lacks in that if they were to implement more rigorous informational requirements
  18. for getting devices through to the market they would improve consumer welfare and that surprises us that
  19. surprised us that the u.s. was so close to optimal given the calls for reforms at the FDA we kind of expected the FDA
  20. to be mean to too difficult to get through the trade off the regulator the regulator has to make is to if you
  21. require more information you delay the introduction of the device and make it more difficult for devices to enter the
  22. market raise the entry cost so the trade-off is that the regulator is making is the increased informational
  23. content of increasingly clinical trials for example in the benefits of that information so that's the kind of the
  24. benefit side the cost is that you delay entry and you and that's a real cost you
  25. have less access to device so there's a real access versus information trade-off
  26. here so one of the things we looked at is how could we improve the process and what we
  27. found is if we could make the post market informational generation process more informative that would generate a
  28. lot of welfare because then we could even relax the pre market requirements more and then more devices would get to
  29. market quicker and so that's the one thing that I think the takeaway is that there's a lot to be gained from
  30. increasing post market surveillance of medical devices hopefully this research will dispel the
  31. notion that the FDA is really way too difficult for particularly second generation devices I think our research
  32. pretty in my view pretty convincingly shows that they actually may be close to doing the right thing
  33. well there really is no other kind of similar analysis out there that's been able to credibly identify the causal
  34. relationship between regulatory regimes and this information content and the benefits that patients get from these
  35. devices so I we think our research is kind of one of a kind and there's some older research thats related to but we
  36. think ours is pretty unique and in that sense so what's next is you know it's we want
  37. to see kind of what market forces are at play that would allow medical device and
  38. cause medical device manufacturers to run their own clinical trials and provide this information on their own
  39. and not through you know requirements of the FDA and kind of providing information to the market and so that's
  40. kind of where we're next going with this research you

Brief Summary

The episode discusses FDA medical device regulation, comparing it to EU standards and suggesting improvements in post-market surveillance for better consumer welfare.

Key points

  • FDA's Regulatory Process. Examining the FDA's approach to medical device regulation and its effectiveness.
  • US vs EU Device Regulation. Comparing the rigorous US standards to the EU's less stringent requirements.
  • Improving Post-Market Surveillance. Research suggests enhancing post-market processes could benefit consumer welfare.

Related episodes